The Impact of Glucagon-Like Peptide-1 Receptor Agonist Use on Clinical Outcomes After Total Hip and Knee Arthroplasty: A Systematic Review and Meta-Analysis of 346,899 Patients

🥉 Top 5% JournalOct 10, 2025The Journal of arthroplasty

Effects of Glucagon-Like Peptide-1 Receptor Agonists on Recovery after Total Hip and Knee Replacement Surgery

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

GLP-1 receptor agonist use was associated with a lower risk of 90-day surgical complications following total knee and hip arthroplasties.

A lower risk of 90-day postoperative joint infections was observed following total knee arthroplasty with GLP-1RA use (odds ratio 0.75).
Total hip arthroplasty patients using GLP-1RAs showed a reduced risk of 90-day revisions (odds ratio 0.76).
GLP-1RA use was linked to decreased 90-day readmission rates for both total knee and hip arthroplasties.
No significant association was found between GLP-1RA use and aspiration or pneumonia risks.
Increased risk of myocardial infarction was noted in total knee arthroplasty patients using GLP-1RAs (odds ratio 1.39).

AI simplified

BACKGROUND: Obesity and diabetes are highly prevalent comorbidities in patients undergoing total hip (THA) and knee arthroplasty (TKA). Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are novel agents that promote weight loss and glycemic control, assisting with perioperative optimization and potentially improving clinical outcomes. However, there have been safety concerns surrounding GLP-1RA use due to delayed gastric emptying and increased aspiration risk. The purpose of this systematic review was to evaluate the impact of GLP-1RA usage on perioperative outcomes following THA and TKA.

METHODS: PubMed (Medline), Scopus (Embase, Medline, and Compendex), and Cochrane databases were queried to conduct a systematic review of articles from inception to June 2025. A total of 13 studies were included (119,092 hip, 227,381 knee, and 426 hip or knee). Demographics, surgical complications, medical complications, resource utilization, and revision rates were recorded at 90 days and at one and two years. Meta-analysis was performed using a random-effects model.

RESULTS: The GLP-1RA use was associated with a lower risk of 90-days PJI following TKA (odds ratio (OR), 0.75; 95% confidence interval (CI), 0.57 to 1.00; P = 0.047) and a lower risk of 90-day revision following THA (OR, 0.76; 95% CI, 0.59 to 0.98; P = 0.034). There was a significant decrease in 90-day readmission rates for TKA and THA with GLP-1RA use. Of note, no significant association was found between GLP-1RA use and aspiration or pneumonia (OR, 1.09; 95% CI, 0.71 to 1.67; P = 0.70), but GLP-1RA usage was associated with an elevated risk of myocardial infarction in the setting of TKA (OR, 1.39; 95% CI, 1.05 to 1.85; P = 0.02).

CONCLUSIONS: The GLP-1RA use was associated with improved early surgical outcomes and decreased resource utilization following THA and TKA. These findings suggest a potential benefit of GLP-1RA use for optimizing high-risk patients who have obesity or diabetes undergoing total joint arthroplasty.

Full Text

Full text is available at the source.

View full text (XML) ↗View full text ↗

Abstract

Full Text

Related papers